Clinical Experience with Bethanidine in Treatment of Hypertension*

Total Page:16

File Type:pdf, Size:1020Kb

Clinical Experience with Bethanidine in Treatment of Hypertension* Byrnsn 2 December 1967 MEDICAL JOURNAL 519 Br Med J: first published as 10.1136/bmj.4.5578.519 on 2 December 1967. Downloaded from Clinical Experience with Bethanidine in Treatment of Hypertension* JULIAN BATH, M.B., B.SC., M.R.C.P.ED.; DOUGLAS PICKERING, M.B., M.R.C.P.ED. RICHARD TURNER, M.D., F.R.C.P., F.R.C.P.ED. Brit. med.JY., 1967, 4, 519-521 At the present time probably most patients with high blood a period with other drugs the change-over was arranged on an pressure in this country are being treated with guanethidine or outpatient basis. The usual reason for change was difficulty methyldopa with or without the addition of an oral diuretic. in controlling the blood pressure, undue postural hypotension, Because of certain disadvantages of these two drugs in our or side-effects. experience (Lowther and Turner, 1963 ; Johnson et al., 1966) TABLE I.-Clinical Features we have largely confined our attention during the past three years to debrisoquine (Kitchin and Turner, 1966) and bethan- Severe Moderate Hypertension Hypertension Total idine. Experience with the latter drug is the subject of this I I~~~~~~~Toa paper. Patient age group: 30-40 4 7 11 41-50 11 8 19 Pharmacology 51-60 13 21 1 34 61-70 11 7 18 Bethanidine is a post-ganglionic adrenergic neurone-blocking Mode of presentation: Left ventricular failure 6 2 8 agent which exerts a marked postural hypotensive effect (Boura Cerebrovascular accident 13 6 19 et al., 1961 ; Boura and Green, 1963; Fewings et al., 1964). In Headache 2 6 8 Dizziness 4 7 11 man sympathetic blockade begins about two hours after a single Visual disturbance 2 0 2 dose, is maximal in four to five hours, and fades in 8 to 12 hours, Angina 1 7 8 Routine examination 11 15 26 but the duration of action depends on the dose administered (Smirk, Blood urea: 1963; Johnston et al., 1964; Wilson et al., 1965). The absorption <40 mg./100 ml. 28 35 63 > 40 mg./100 ml. 11 8 19 and excretion of `C bethanidine in man was studied by Doyle and E.C.G.: who showed that after oral administration L.V. hypertrophy present.. 34 8 42 Morley (1965), absorp- L.V. hypertrophy absent 5 35 40 tion was rapid and almost complete. Excretion is almost entirely Retinal changes: in the the rate on the filtration rate. Normal 0 11 11 urine, depending glomerular Grade I-II. 21 27 48 Other studies have shown the renal clearance of inulin and of para- Grade III. 15 20 acid to be reduced in bethan- Grade IV 3 5 3 aminohippuric slightly patients given Resting diastolic pressure idine (Esch and Krammer, 1965). before treatment: 105-129 (mm. Hg).. 15 22 37 The precise mechanism whereby bethanidine causes blockade of 130-149 ,. 18 14 32 adrenergic neurones is unknown (Boura and Green, 1965). An 150+ 6 7 13 initial sympathomimetic effect has been demonstrated in man and 7 animals, possibly due to release of catecholamines, for it is blocked The initial dose of bethanidine was usually 5 mg. twice daily. et by phenoxybenzamine (Fewings al., 1964), and increased sensi- were every Increments made third day in hospital patients and http://www.bmj.com/ tivity to noradrenaline after bethanidine further suggests peripheral every week in those being treated at home until an adequate release of catecholamines by this drug. Bethanidine resembles bretyliumtosylate and debrisoquine in that blockade is achieved response was obtained. Frequency of attendance at the clinic without early depletion of tissue catecholamines, in this respect depended on the degree of control or the presence of side-effects. differing from guanethidine and guanoclor. However, large doses The daily dose ranged from 10 to 120 mg., with an average of of bethanidine over long periods reduce catecholamines in some 32.5 mg. in the initial stages and 43 mg. later on. tissues (Boura et al., 1961). Unless administered in very high As in previous studies of antihypertensive drugs the aim of concentration bethanidine does not block or motor- cholinergic treatment was to reduce the standing diastolic pressure to as neurone and activity (Boura Green, 1963). near normal levels as could be achieved without undue side- on 23 September 2021 by guest. Protected copyright. effects. In patients with cerebral or coronary atherosclerosis or Material and Methods with a persistently raised blood urea the blood pressure was lowered more cautiously and reduction to a standing diastolic Between September 1964 and March 1967 70 patients were level of 100-105 mm. was as a treated with bethanidine for periods ranging from six to 24 Hg regarded satisfactory result. the fall in pressure achieved and maintained months: 23 were followed up for six to 12 months, 10 for 13 Only has been considered in the results of treatment. A " to 18 months, 22 for 19 to 24 months, and 15 for 25 to 30 classifying " good result a fall in diastolic mm. months. In addition 12 patients stopped treatment earlier for signifies pressure to below 100 Hg. A " fair " result a fall of diastolic pressure to between reasons discussed below. Ages ranged from 21 to 66 years. signifies 100 and 110 mm. Hg. A "poor" result denotes failure to Of the 82 patients 41 were made and 41 female. Table I maintain a diastolic below mm. includes the age distribution related to severity of the disease. pressure 110 Hg. It will be appreciated that a precise classification is not possible because Indications for selection of of treatment, patients, methods in some patients the deliberate aim has been to achieve a fair blood criteria of and classifica- pressure measurement, severity, result as defined by reduction in blood pressure. tion of results were similar to those we have already described in relation to the other drugs except that this series includes The results have been tabulated for each patient at intervals more relatively young patients without evidence of secondary of six months. changes in the heart or fundi. Results Half the patients had previously received treatment with other antihypertensive drugs. Most new patients were admitted Of the original 82 patients, four died, seven discontinued to hospital for assessment of the severity and type of their bethanidine because of side-effects, and one defaulted before hypertension and the initiation of appropriate treatment. In the end of six months. The remaining 70 all completed at some who had been fully assessed previously and treated for least six months of treatment (Table II). After six months one * University Department of Medicine and the Cardiac Department of the patient discontinued the drug because Western General Hospital, Edinburgh 4. of side-effects, two defaulted, and seven died. At the end of 520 2 December 1967 Hypertension-Bath et al. MEDICAL JOURNAL TABLE II.-Results The incidence of side-effects bore no obvious relation to the Br Med J: first published as 10.1136/bmj.4.5578.519 on 2 December 1967. Downloaded from initial severity of hypertensive disease, the presenting symptoms, Patients Total Control associated atherosclerosis, the degree of blood pressure control, Moderate | Severe No - % or subsequent death. As with other antihypertensive drugs the Good 15 15 30 43 At 6 months .. Fair 13 8 21 30 incidence between individuals was most variable. Poor 9 10 19 27 Good 12 12 24 52 At 12 months .. { Fair 10 3 13 28 Poor 3 7 10 20 Oral Diuretic Supplements Good 13 8 21 56 At 18 months .. { Fair 5 3 8 22 In order to facilitate comparison with other drugs it had Poor 2 6 8 22 been intended, if possible, to treat all patients with bethanidine Good 4 5 9 60 At 24 months .. { Fair 3 1 4 27 alone. However, it became necessary to add an oral diuretic Poor 1 1 2 13 in 28 cases on account of difficulty in controlling the pressure, side-effects, or fluid retention. six months 73 % of patients had good or fair control of their As can be seen from Table III the mean daily dose of blood pressure. Results improved with continued treatment bethanidine was gradually increased for most patients. In 19 and adjustment of dosage with or without the addition of an cases the dose was increased to improve control and in seven oral diuretic, the or proportion having good fair control rising to regain control on account of tolerance. An oral diuretic to 80% after 12 months and to 87% in the 15 patients who was added to improve control in six and to regain control in had been treated for two years. Most of the poor results were two patients. The fact that supplementary oral diuretics were in patients with severe hypertension. used in 34% of all patients reflects the difficulty experienced Of the 19 patients in whom initial control was unsatisfactory in achieving satisfactory control with freedom from excessive 13 continued treatment for 12 months or more. Good or fair postural hypotension when using bethanidine alone. In a few control was achieved in five by increasing the dose and in three cases a diuretic was used from the start because rapid control more by the addition of an oral diuretic. Of the five patients of the blood pressure or a diuresis was required. Diuretics in whom control was persistently poor two had severe cerebral were used in a proportionately larger number of patients the atherosclerosis, one uraemia, one asthma requiring corticosteroid longer treatment continued, because of an increased tendency therapy, and one cor pulmonale. Temporary failure of control to make this addition whenever difficulty with control or side- was attributed to tolerance in two patients and to side-effects effects was experienced.
Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • 9719087.Pdf (3.190Mb)
    US009719087B2 a2) United States Patent (0) Patent No.: US 9,719,087 B2 Olson et al. (45) Date of Patent: *Aug. 1, 2017 (54) MICRO-RNA FAMILY THAT MODULATES A61LK 39/3955 (2013.01); AGLK 45/06 FIBROSIS AND USES THEREOF (2013.01); A6IL 31/08 (2013.01); AGIL 31/16 (2013.01); C12N 9/16 (2013.01); C12N (71) Applicant: THE BOARD OF REGENTS, THE 15/8509 (2013.01); AOIK 2207/30 (2013.01); UNIVERSITY OF TEXAS SYSTEM, AOIK 2217/052 (2013.01); AOLK 2217/075 Austin, TX (US) (2013.01); AOIK 2217/15 (2013.01); AOIK 2217/206 (2013.01); AOIK 2227/105 (72) Inventors: Erie N. Olson, Dallas, TX (US); Eva (2013.01); AOIK 2267/0375 (2013.01); AIL van Rooij, Utrecht (NL) 2300/258 (2013.01); A6IL 2300/45 (2013.01); : AOIL 2420/06 (2013.01); C12N 2310/113 (73) Assignee: THE BOARD OF REGENTS, THE (2013.01); CI2N 2310/141 (2013.01); CI2N UNIVERSITY OF TEXAS SYSTEM, 2310/315 (2013.01); C12N 2310/321 Austin, TX (US) (2013.01); C12N 2310/346 (2013.01); C12N (*) Notice: Subjectto any disclaimer, the termbe this (013.01ars orb01301CDN US.C.patent154(b)is extendedby 0 ordays.adjusted under 2320/32 (2013.01);4 . CI2N 2330/10yor(2013.01) (58) Field of Classification Search This patent is subject to a terminal dis- CPC vieceeceseeseeeeeeee C12N 15/113; C12N 2310/141 claimer. See application file for complete search history. — (21) Appl. No.: 14/592,699 (56) References Cited (22) Filed: Jan. 8, 2015 U.S. PATENT DOCUMENTS (65) Prior Publication Data 7,232,806 B2 6/2007 Tuschlet al.
    [Show full text]
  • Drugs Affectin the Autonomic Nervous System
    Fundamentals of Medical Pharmacology Paterson Public Schools Written by Néstor Collazo, Ph.D. Jonathan Hodges, M.D. Tatiana Mikhaelovsky, M.D. for Health and Related Professions (H.A.R.P.) Academy March 2007 Course Description This fourth year course is designed to give students in the Health and Related Professions (H.A.R.P.) Academy a general and coherent explanation of the science of pharmacology in terms of its basic concepts and principles. Students will learn the properties and interactions between chemical agents (drugs) and living organisms for the rational and safe use of drugs in the control, prevention, and therapy of human disease. The emphasis will be on the fundamental concepts as they apply to the actions of most prototype drugs. In order to exemplify important underlying principles, many of the agents in current use will be singled out for fuller discussion. The course will include the following topics: ¾ The History of Pharmacology ¾ Terminology Used in Pharmacology ¾ Drug Action on Living Organisms ¾ Principles of Pharmacokinetics ¾ Dose-Response Relationships ¾ Time-Response Relationships ¾ Human Variability: Factors that will modify effects of drugs on individuals ¾ Effects of Drugs Attributable to Varying Modes of Administration ¾ Drug Toxicity ¾ Pharmacologic Aspects of Drug Abuse and Drug Dependence Pre-requisites Students must have completed successfully the following courses: Biology, Chemistry, Anatomy and Physiology, Algebra I and II Credits: 5 credits Basic Principles of Drug Action Introduction to Pharmacology a. Basic Mechanisms of Drug Actions b. Dose-response relationships c. Drug absorption d. Biotransformation of Drugs e. Pharmacokinetics f. Factors Affecting Drug Distribution g. Drug Allergy and Pharmacogenetics h.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Family Practice Forum Reserpine: the Maligned Antihypertensive Drug
    Family Practice Forum Reserpine: The Maligned Antihypertensive Drug Reuben B. Widmer, MD Oakdale, Iowa During the 1950s reserpine was introduced to evaluation of reserpine and depression by Good­ physicians in the United States as an effective win and Bunney6 described the early use of re­ psychotropic and antihypertensive drug. Within a serpine in a table format, which outlined dosages few years clinicians reported depression and sui­ used (0.25 to 10 mg) and degree of depression diag­ cide in psychotic and hypertensive patients who nosed. The studies from the 1950s had reported an had been administered reserpine in dosages of 0.5 average incidence of depression of 20 percent. Be­ to 10 mg/d.1-4 However, a causal link between re­ cause there was no minimal criteria identification, serpine and depression has never been adequately the clinical criteria the authors used to diagnose established,5,6 and recent studies have shown that depression were not always clear. There was also reserpine in dosages under 0.5 mg is a safe and a considerable difference in the lag period between efficacious antihypertensive medication.7-9 starting the drug and the appearance of depression A 1971 review of the literature and a 1972 re- (2 weeks to 1 year).5,6 In 1958 Ayd10 described two syndromes that occurred with reserpine in dosages up to 10 mg/d: “ Pseudodepression,” characterized by a feeling of lassitude and discouragement, and “ true depres­ From the Department of Family Practice, College of Medi­ sion,” which included the symptoms of a major cine, University of Iowa, Iowa City, Iowa.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://edhub.ama-assn.org/ on 09/24/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0293552 A1 Gorczynski (43) Pub
    US 20070293552A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0293552 A1 Gorczynski (43) Pub. Date: Dec. 20, 2007 (54) ANTIHYPERTENSIVE THERAPY METHOD Publication Classification (76) Inventor: Richard J. Gorczynski, Westminster, (51) Int. Cl. CO (US) A6II 3/42 (2006.01) (52) U.S. Cl. .............................................................. S14/378 Correspondence Address: (57) ABSTRACT HARNESS, DICKEY, & PIERCE, P.L.C Methods and therapeutic combinations are provided for 7700 BONHOMME, STE 400 lowering blood pressure in a Subject exhibiting resistance to ST. LOUIS, MO 63105 (US) a baseline antihypertensive therapy with one or more drugs, or a subject having diabetes and/or chronic kidney disease. A method of the invention comprises administering, in some (21) Appl. No.: 11/761,499 embodiments adjunctively with a modified baseline therapy, a compound of formula (I) as defined herein. A therapeutic (22) Filed: Jun. 12, 2007 combination of the invention comprises a compound of formula (I); at least one diuretic; and at least one antihy pertensive drug selected from ACE inhibitors, angiotensin II Related U.S. Application Data receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers; wherein the at least one diuretic (60) Provisional application No. 60/813.966, filed on Jun. and/or the at least one antihypertensive drug are present at 15, 2006. substantially less than a full dose. US 2007/0293552 A1 Dec. 20, 2007 ANTHYPERTENSIVE THERAPY METHOD signaling pathways. While antagonism of the ETA receptor is known to reduce endothelin-mediated vasoconstriction, 0001. This application claims the benefit of U.S. provi antagonism of the endothelin-B (ET) receptor can block sional application Ser.
    [Show full text]
  • Drugs Acting on the Sympathetic System 9
    MPAC09 8/6/05 1:45 pm Page 24 9 Drugs acting on the sympathetic system Noradrenergic nerve terminal Sympathomimetics Adrenergic neurone Deaminated Indirectly acting metabolites blockers ephedrine Displace NE reserpine amfetamine tyrosine guanethidine (tyramine) bethanidine cocaine Prevents tyrosine storage tyrosine Adrenoceptor Directly acting hydroxylase α Uptake 1 antagonists -AGONISTS MAO α α dopa 1/ 2 α-BLOCKERS dopa norepinephrine α α NE decarboxylase 1/ 2 epinephrine NE Prevents phenoxybenzamine α dopamine (DA) release 2 phentolamine NE – clonidine NE α 1 α-methyl- DA dopamine prazosin norepinephrine β-hydroxylase ATP e α NE NE s β 1 la r -BLOCKERS P c o + M y t phenylephrine NE A lc p β β c ly e 1/ 2 y ec metaraminol en -r – d α 2 propranolol + a NE β-AGONISTS nadolol β β – U timolol 1/ 2 pt ake epinephrine 1 Ca2+ oxprenolol * isoprenaline pindolol* β Inactivation carvedilol 2 β (cardioselective) Metabolites 1 salbutamol metoprolol terbutaline atenolol β NE 1 Uptake 2 acebutolol* norepinephrine + dobutamine MAO + – COMT tor β α recep * Partial agonist activity -rec 1- e C eptors ipas Most lipid soluble phol aden phos Least lipid soluble ylyl cyclase InsP3 + DG ATP cAMP Sympathetic effects The sympathetic nervous system is important in regulating organs such agonists (dobutamine) are sometimes used to stimulate the force as the heart and peripheral vasculature (Chapters 15 and 18). The trans- of heart contraction in severe low-output heart failure (Chapter 18). α mitter released from sympathetic nerve endings is norepinephrine 1-Agonists (e.g. phenylephrine) are used as mydriatics (Chapter 10) α (NE) (noradrenaline, ) but, in response to some forms of stress, and in many popular decongestant preparations.
    [Show full text]